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Induction of HIV-1 broad neutralizing antibodies
(bnAbs) is a goal of HIV-1 vaccine development but
has remained challenging partially due to unusual
traits of bnAbs, including high somatic hypermuta-
tion (SHM) frequencies and in-frame insertions and
deletions (indels). Here we examined the propen-
sity and functional requirement for indels within
HIV-1 bnAbs. High-throughput sequencing of the
immunoglobulin (Ig) VHDJH genes in HIV-1 infected
and uninfected individuals revealed that the indel
frequency was elevated among HIV-1-infected sub-
jects, with no unique properties attributable to
bnAb-producing individuals. This increased indel
occurrence depended only on the frequency of
SHM point mutations. Indel-encoded regions were
generally proximal to antigen binding sites. Addition-
ally, reconstruction of a HIV-1 CD4-binding site bnAb
clonal lineage revealed that a large compound VHDJH
indel was required for bnAb activity. Thus, vaccine
development should focus on designing regimens
targeted at sustained activation of bnAb lineages to
achieve the required SHM and indel events.
INTRODUCTION
With the use of antigen-specific memory B cell isolation and anti-
body rescue techniques, a large number of HIV-1 broad neutral-304 Cell Host & Microbe 16, 304–313, September 10, 2014 ª2014 Elizing antibodies (bnAbs) have been isolated (Haynes et al., 2011).
All bnAbs share one or more unusual traits such as autoreactiv-
ity, long heavy-chain third complementarity-determining regions
(HCDR3s), and high levels of somatic hypermutation (Walker
et al., 2009,2011; Haynes et al., 2005, 2012; Kwong and Mas-
cola, 2012; Mouquet and Nussenzweig, 2012; Wu et al., 2010,
2011; Zhou et al., 2010; Mascola and Haynes, 2013; Liao et al.,
2013), all traits that can limit the induction of such antibodies
(Haynes et al., 2005, 2012; Mascola and Haynes, 2013; Verkoczy
et al., 2011).
Some recently isolated HIV-1 bnAbs have been noted to
possess another unusual characteristic: multibase in-frame in-
sertions or deletions (indels) (Wu et al., 2010; Walker et al.,
2011). Indels are introduced during somatic hypermutation and
are thus found exclusively in germinal center or postgerminal
center B cells (Fukita et al., 1998). The proportion of indels among
somatic mutations in the normal human B cell repertoire is small.
Wilson et al. examined IgG memory cells from human tonsil and
reported six indels in 110,000 bases sequenced from productive
genes, comprising both 3- and 6-base insertions and deletions
(Wilson et al., 1998). Using high-throughput sequencing, Briney
et al. (2012) found slightly higher frequencies of in-frame inser-
tions (1.8% of all sequences) and in-frame deletions (2.0%–
2.6% of all sequences) in FACS-sorted memory B cells. Smith
et al. (1996) studied unselected mutations in the introns between
the JH and constant region genes and found that 1%–2% of all
unselected somaticmutations were single-base insertions or de-
letions. When indels do occur in normal B cells, they are usually
short; their frequency decreases rapidly with length (Wilson
et al., 1998). Here we have surveyed bnAb sequences and found
that 40% of reported HIV-1 bnAbs have indels and that the indel
sizes cover the remarkable range from 3 to 33 nucleotides.sevier Inc.
Table 1. Insertions and Deletions in Broadly Neutralizing Anti-
HIV-1 Antibodies
Antibody Indel Type Length Location
CAP206-CH12 Deletion 3 aa HFR3
NIH45-46 Deletion 6 aa LCDR1
HJ16 Deletion 3 aa HCDR2
HJ16 Insertion 3 aa LFR3
VRC01 Deletion 6 aa LCDR1
VRC03 Insertion 21 aa HFR3
CH98 Deletion 15 aa LFR1
CL103 Deletion 9 aa LFR1
PGT121-3 Insertion 9 aa LFR3
PGT125-8 Insertion 18 aa HCDR2
PGT125-8 Deletion 15 aa LCDR1
PGT136 Insertion 3 aa HCDR2
PGT135-7 Insertion 15 aa HCDR1
PGT135-7 Insertion 3 aa LFR1
PGT145 Deletion 3 aa HCDR3
PG9 Insertion 3 aa HFR1
CH30-34 Insertion 27 aa HCDR1
3BNC117, 3BNC60 Insertion 12 aa HFR3
3BNC117, 3BNC60 Deletion 12 aa LCDR1
8ANC131, 8ANC134 Deletion 3 aa HCDR2
8ANC131, 8ANC135 Deletion 3 aa LCDR1
8ANC195 Deletion 3 aa HCDR1
8ANC195 Insertion 15 aa HCDR2
8ANC195 Insertion 3 aa LCDR1
VRCPG04,04B Deletion 9 aa LCRD1
VRCPG04,04B Insertion 3 aa HCDR1
VRCPG04,04B Insertion 3 aa HFR3
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Indels in HIV-1 Broadly Neutralizing AntibodiesBecause induction of bnAbs may be central to HIV-1 vaccine
development efforts, it is of great interest to determine why in-
dels occur at such great frequency in bnAbs. There are several
hypotheses regarding the cause of this striking bias. Perhaps
patients who produce bnAbs have an underlying propensity to
incorporate indels during affinity maturation. Another possibility
is that chronic HIV-1 infection induces the generation of indels
and that indels will be found at greater frequencies in all HIV-1-
infected patients. It is also possible that there are genetic poly-
morphisms that affect the somatic hypermutation mechanism
and predispose carriers to produce high levels of somatic hyper-
mutations and indels during the induction of bnAbs. If genetic
polymorphins are the cause for elevated SHMs, it would have
serious consequences for the development of vaccines to elicit
bnAbs, in that only those with such a genetic background will
be able to make vaccine-induced bnAbs. In addition, it is impor-
tant to know whether indels can be required for bnAb activity. To
test these ideas, we examined heavy-chain sequences fromHIV-
1-infected individuals who make bnAbs, as well as from HIV-1-
infected individuals who do not. To determine the functional
consequences of insertion/deletion events, we made a detailed
reconstruction of a VRC01-like CD4 binding site bnAb (CH31)
clonal lineage and demonstrated that a large compound indelCell Host & Mwas essential for both bnAb affinity maturation and HIV-1
neutralization.
Indels Are Found at High Frequency among HIV-1 bnAbs
Many of the recently isolated bnAbs have been observed to have
insertions or deletions. To determine whether the occurrence of
indels in bnAbs is disproportionally high, we examined the re-
ported 56 HIV-1 bnAb gene pairs (Table S1), which constituted
26 sets of clonally related heavy- and light-chain genes. Among
these genes, we identified 27 unique in-frame indels. Half of
these indels were 3 nt long, but insertions as large as 33 nt and
deletions up to 15 nt were also observed (Table 1). Overall, 40
of the 108 bnAb genes contained indels. Counting unique indels
only, the frequency of indels in this group of genes was 27/108
(25%). This rate is nearly seven times higher than that observed
in a collection of 13,000 human heavy-chain variable regions
downloaded from NCBI GenBank. Thus, the frequency of indels
among bnAbs is elevated.
To determine whether the high frequency of indels in bnAbs
was attributable to an increase in the frequency of indel-bearing
antibodies generally in all chronically infected HIV-1-infected
individuals, versus selective increaseof indels inbnAb-producing
individuals, we determined the frequency of indels in unbiased
samples of Ig variable region genes from blood B cells using
Roche 454 high-throughput DNA sequencing (HTS) of full-length
genomic VHDJH rearrangements. We generated and analyzed
HTSdata comprising 3,778,439sequencing reads from261sam-
ples taken at different times from 75 human subjects. These indi-
viduals included 41 HIV-infected individuals (8 bnAb producers
and 33 non-bnAb producers), 18 influenza-vaccinated individ-
uals, and 16 HIV-1-uninfected individuals (Tables S2 and S3).
After discarding sequences rearranged out of frame or con-
taining frame-shifting indels, we analyzed a total of 3,352,720 se-
quences using statistical methods and software developed for
this purpose (Kepler, 2013). All alignments between sequencing
reads and gene segments used an affine gap scoring function
(Gotoh, 1990). Each sequence was scored either as containing
or not containing an in-frame insertion and/or deletion.
We found that VHDJH genes from HIV-1-infected bnAb and
non-bnAb subjects have higher levels of indels than do
those from healthy influenza-vaccinated and non-HIV-1-infected
groups (Figures 1A and 1B). Compared to non-HIV-1-infected
subjects, the geometric mean insertion frequency was 27%
higher in HIV-1-infected individuals (p = 0.03; ANOVA); the
geometric mean deletion frequency was similarly 23% higher
in HIV-1-infected individuals (p = 0.03; ANOVA). Importantly,
with HIV-1-infected individuals, indel frequencies did not signif-
icantly differ between bnAb-producing and nonproducing sub-
jects (p > 0.1 in both cases; Tukey multiple-comparisons test).
Mean Indel Frequency Is Predicted by Mean
Mutation Frequency
The frequency of pointmutations is similarly elevated in HIV-1-in-
fected individuals (ANOVA p < 0.01 for differences attributable
to subject classification; Tukey multiple comparisons, p < 0.05
for differences specific to HIV-1 status). This result raises the
possibility that both point mutation and indel frequencies are
increased together by the same underlying cause. We hypothe-
sized that since indels are induced by the same mechanism asicrobe 16, 304–313, September 10, 2014 ª2014 Elsevier Inc. 305
Figure 1. Comparison of VH Mutation Frequencies in HIV-1 bnAbs with Those in Other Antibodies
(A and B) Box plots showing centered log frequencies (cyan) for in-frame insertions (A) and deletions (B) per 105 VH bases in potentially functional heavy-chain
genes, and insertion and deletion log frequency residuals (blue) after subtracting log frequency predicted from substitution frequency alone. Subject classifi-
cations: subjects known to produce broadly neutralizing antibodies against HIV-1 (bnAb), subjects who had been vaccinated against influenza 1 week prior to
sampling (influenza vaccinee), HIV-1-infected subjects who had not produced bnAbs by the time of this study (HIV no bnAb), and uninfected controls (control).
Boxes cover from the first to the third quartiles; whiskers extend to the standard span—1.5 times the interquartile range. Cyan boxes were centered by sub-
tracting the mean frequency over all subjects; blue boxes were not centered.
(C and D) Log of the insertion frequency per 105 bases (C) and deletion frequency (D) as a function of the log of the substitution frequency per base. The colored
line segments show the linear regression for each of the subject classifications; the gray line segment shows the linear regression for all subjects at once.
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Indels in HIV-1 Broadly Neutralizing Antibodiespoint substitutions, a higher overall mutation level could account
for the higher indel frequency. To evaluate this possibility, we
performed linear regressions of log average insertion or deletion
frequency against the log of the substitution frequency. The re-
gressions were performed with separate regression coefficients
for each subject classification group as well as with a common
regression coefficient for all subjects. The regression coeffi-
cients were not statistically different among subjects for either
insertions or deletions (p > 0.1, ANOVA; Figures 1C and 1D);
the estimate (±SE) for the common regression coefficient was
1.95 ± 0.13 for insertions and 1.44 ± 0.22 for deletions. Figures
1A and 1B also show the residuals remaining after subtracting
the insertion and deletion frequencies predicted using the com-
mon-coefficient regression models, illustrating that most of the
variability among classifications was attributable to differences
in point substitution frequency.306 Cell Host & Microbe 16, 304–313, September 10, 2014 ª2014 ElWe were able to study nine HIV-1-infected individuals (five
among the bnAb-producers and four among the non-bnAb
producers) with VHDJH sequencing data from three or more
sampling times. The frequency of indel-containing sequences
was variable over time (Figure 2). Simple linear regression of
insertion or deletion frequencies against days postinfection
found regression coefficients for insertion significantly greater
than zero in two out of nine cases (p < 0.05), while eight out
of nine regression coefficient estimates were positive, signifi-
cantly more than expected if there were no temporal trend
(p = 0.004, two-sided sign test). No such trend was evident
for deletions—no correlation coefficients differed statistically
from zero, and four out of nine were positive. Although indel
frequency is volatile, there is a weak but detectable tendency
for insertions, but not deletions, to increase over time with HIV
infection.sevier Inc.
Figure 2. Time Course of In-Frame Insertion and Deletion Fre-
quencies in Days Postinfection for HIV-Infected Subjects
Time course of in-frame insertion (A) and deletion (B) frequencies. The five
subjects known to produce bnAbs are indicated with solid lines; the four who
have not made bnAbs are indicated with dashed lines. Only subjects with
samples taken at three or more times were included.
Cell Host & Microbe
Indels in HIV-1 Broadly Neutralizing AntibodiesTo address the question of whether chronic infections other
than HIV are associated with increased rates of insertions and
deletions, we examined HTS heavy-chain Ig repertoire data
from subjects chronically infected with cytomegalovirus (CMV),
Epstein-Barr virus (EBV), both viruses, or neither (Wang et al.,
2014). There were no detectable differences among these
groups in the rates of in-frame insertions or deletions (p > 0.1,
ANOVA; Figure S2).
Indel Placement and Antigen Recognition
To determine whether indels in bnAbs were preferentially found
in antigen-interacting regions or were more randomly distrib-
uted, we analyzed a set of 11 antigen-bound bnAb structures
containing a total of 18 indels (Supplemental Experimental
Procedures). Fifteen of 18 (83%) indels were found within 10 A˚
of the respective antigen binding site (Figure 3). In comparison,
analysis of loop regions (assumed to be able to more easily
accommodate indels due to fewer structural constraints com-
pared to beta strand regions) revealed that only approximatelyCell Host & Mone-third of loop residues were found within 10 A˚ of the res-
pective antigen, even when removing potential skewness due
to overrepresentation of specific antibody classes (Figure S1).
The distributions of the indel and loop residue locations were
significantly different (p < 0.0001, Mann-Whitney test). These re-
sults indicated that while there was little constraint on the loca-
tion where indels can be accommodated, their presence related
directly to antigen recognition. One potential caveat of this anal-
ysis is that proximity to antigen was measured based on the Env
subunit antigen constructs in the available crystal structures,
rather than a functional HIV-1 spike, thus possibly underestimat-
ing the proximity to antigen for some indels. Overall, indels were
preferentially found in close proximity to antigen binding sites,
and thus likely improved interactions with antigen.
The Indel in VRC01-like CD4 Binding Site CH30-CH34
Clonal Lineage Was Required for bnAb Affinity
Maturation
Wehave recently reported the occurrence of two different sets of
clonally related bnAbs in the same HIV-1-infected individual that
together accounted for all of the plasma bnAb activity (Wu et al.,
2011; Bonsignori et al., 2012). This individual (CH0129) had both
VRC01-like CD4 binding site and V1V2 quaternary bnAb activity
(Bonsignori et al., 2011, 2012). The VRC01-like CD4 binding-site
clone CH30–CH34 experienced indel formation, while the V1V2
PG9-like bnAb clonal lineage CH01–CH04 did not. We recon-
structed the corresponding CH31 clonal lineage using statistical
inference on the originally isolated genes, supplemented with
targeted HTS reads to determine the affinity maturation history
and the role of indel in affinity maturation and acquisition of
neutralization breadth in the observed CH31 lineage CD4bs
antibodies (Figure 4; Table 2).
The members of the CH31 clonal lineage are similar to other
VRC01-like bnAbs clone in their use of the VH1-2*02 gene
segment (Wu et al., 2011; Bonsignori et al., 2012). Moreover,
the crystal structure of CH31 complexed to gp120 is superim-
posable on that of VRC01 (Zhou et al., 2013). Most strikingly,
perhaps, is the observation that both VRC03 (a member of the
VRC01 clonal lineage) and all the members of the CH31 clonal
lineage contain large indels. VRC03 has a 21 nt insertion in
framework region 3. The CH31 clonal lineage genes have a net
27 nt insertion within CDR1 that resolves into a 6 nt deletion
and a 33 nt tandem duplication (Figure 4A). Using HTS targeted
at VHDJH genes rearranging to the VH and JH gene segments
used by CH31 lineage antibodies, we were able to isolate genes
situated close to the inferred unmutated common ancestor
(UCA) on the clonal tree and prior to the indels. Importantly, we
isolated 14 unique VHDJH genes that were clearly members of
the CH31 clonal lineage but did not have the indel, as well as iso-
lated several hundred more mutated VHDJH genes that did have
the indel (Figure 4C).
The CH31 clonal lineage history demonstrated a striking
accumulation of mutations in the vicinity of the eventual indel,
including the formation of an activation-induced cytidine deam-
inase (AID) AGC hotspot that probably contributed to the genetic
instability responsible for the indel (Figure 4A). Indeed, a feature
common to all of the bnAbs that have experienced indels is an
accumulation of point mutations on either side of the insertion
or deletion (Figure S1).icrobe 16, 304–313, September 10, 2014 ª2014 Elsevier Inc. 307
Figure 3. Structural Analysis of Antibody Indels
(A and B) Distribution of distances between antigen and indels (A) or loop residues (B). These distributions are statistically distinguishable (p < 0.0001, Mann-
Whitney test). Distances are shown as bins in 5 A˚ increments.
(C–F) Location of insertions and deletions in antigen-bound structures of antibodies VRC-CH31 (C), VRC01 (D), 3BNC117 (E), and PGT128 (F). Structures are
shown in ribbon representation with antibody heavy chains in green, light chains in blue, and the respective antigens in gray. For PGT128, antibody-interacting
glycans on antigen are shown as gray sticks. The regions where insertions and deletions were observed are highlighted in yellow and red, respectively. See also
Figure S1.
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Indels in HIV-1 Broadly Neutralizing AntibodiesWenext expressed antibodymembers of the CH31 clonal line-
age representative of key stages along the maturation pathway
as well as four artificial heavy-chain constructs (Figure 4B) that
were intended to probe the specific contributions of the indel
to the affinity, kinetic parameters, and neutralization capacity
of CH31 bnAb lineage antibodies generated before and after in-
del occurrence.
Consider the line of descent leading from the UCA to the
mature antibodies CH30–CH34 (Figure 4B). GNM7S is an ob-
served heavy-chain sequence lying just off the line of descent.
It arose just before the indel was acquired and is the indel-free
sequence farthest from the UCA. Among postindel sequences,
H162G is closest to the UCA along the line of descent. GNM7S
and H162G differ by 16 nucleotide substitutions in addition to
the indel. The differences between the two in terms of their bio-
physical properties are likely due both to the indel and the nucle-
otide substitutions. To isolate the influence of the indel from the
influence of the simple substitutions, we designed and synthe-
sized four heavy chains that represent hybrids of antibodies
H162G and GNM7S involving inclusion or removal of the tandem
duplication.308 Cell Host & Microbe 16, 304–313, September 10, 2014 ª2014 ElThe relationships between the observed and synthetic se-
quences are shown schematically in Figure 4B. Each heavy
chain sequence can be decomposed into three elements: the
duplicated element, or duplicon (Eichler, 1998), and the elements
50 and 30, respectively, of the duplicon. The 50 element is denoted
A, the duplicon D, and the 30 element B. The structure of GNM7S
is given by A0 D0 B and that of H162G is A1 D1 D2 B. The dupli-
cons D0, D1, and D2 are homologous 33 nucleotide tracts that
differ from each other by 5–13 nucleotides. A0 and A1 differ
from each other by 17 nucleotide substitutions and a 6 nucleo-
tide deletion. GNM7S and H162G share an identical B element.
The following four antibody heavy chains were synthesized by
adding a duplicon to GNM7S (A1 D1 D0 B and A1 D0 D2 B) or de-
leting a duplicon from H162G (A1 D1 B and A1 D2 B). Each artifi-
cial heavy chain was paired with the light chain of a statistically
inferred postinsertion antibody for full antibody expression.
We estimated antibody binding kinetic parameters affected by
the indel by surface plasmon resonance (SPR) analysis of CH31
lineage members binding to HIV-1 AE.A244 gp120 (Alam et al.,
2013). Figure 5 shows that, in the natural CH31 lineage, the as-
sociation rate of lineage antibodies for AE.A244 gp120 bindingsevier Inc.
Figure 4. Maturation Pathway of CD4BS bnAb CH31 Clonal Lineage
(A) Alignment of the observed CD4BS bnAb CH31 and observed CH31 clonally related VHDJH sequences from HTS shows the likely duplication and deletion
events leading to the mature antibody. An AID hot spot ‘‘AGC’’ at alignment position 162 (red line segment) appears as a result of nucleotide substitution in
2GNM7S. Dots indicate identity with the nucleotides in the UCA; dashes represent gaps. Shading of the sequences corresponds to the schematic deconstruction
in (B).
(B) A schematic showing the structures of the observed heavy chains (2GNM7S, 2H162G) in terms of the sequence elements A, A’; D0, D1, D2, and B, and the
artificial constructs made by inserting and deleting the duplicons.
(C) A maximum-likelihood tree incorporating all antibody members (CH30–CH34) of the CH31 clonal lineage VHDJH and the VHDJH isolated by HTS. The VHDJH
genes indicated in blue boxes have been synthesized and paired with intermediate-4 light chain for production of recombinant monoclonal antibodies for testing
the binding and neutralizing activity. The compound insertion-deletion event occurred on the branch indicated by the red asterisk. The asterisks on the sequence
titles 2H4SHE and 2G9LMX indicate that each of these sequences has hundreds (**) or tens (*) of closely related sequences not shown on the tree.
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Indels in HIV-1 Broadly Neutralizing Antibodiesincreased and the dissociation rate decreased with evolutionary
distance (in expected number of mutations per base) from the in-
ferred UCA. The artificial antibody constructs in which an indel
duplicon was inserted but no other changes made showed that
this single change brought about an 8-fold increase in the asso-
ciation rate (Figure 5A). When the indel duplicon was deleted
from the postindel heavy chain, the association rate of the anti-
body for binding to AE.A244 gp120 decreased by an order of
magnitude (2H162G-D1; Figure 5A). The dissociation rate was
slightly decreased by insertion of the duplicon from 2GNM7S
to both 2GNM7S+D1 and 2GNM7S+D2. Upon its deletion, how-
ever, the dissociation rate was increased 3-fold (2H162G-D1;
Figure 5B). No antibodies less diverged than 2JSKAU from the
UCA showed binding of any measurable degree to AE.A244
gp120 (data not shown).
Broad Neutralization by CH31 Antibody Is Acquired after
Indel Formation
Finally, we assayed members of the CH31 clonal lineage for their
ability to neutralize heterologous HIV-1 strains in the TZBbl
neutralization assay (Table 2). We found that neutralization
breadth did not arise until after the occurrence of the indel. The
only tier 2 (difficult to neutralize) strain neutralized before the in-
del was A.Q23, with neutralization of other strains only acquiredCell Host & Mafter the indel with antibodies 2H162G and 2H4HE representing
the point in the CH31 lineage with neutralization breadth.
DISCUSSION
In this study, we have demonstrated the high frequency of indels
among HIV-1 broad neutralizing antibodies, showed that these
ndels occur predominantly near bnAb antigen contact sites,
and demonstrated an example of the requirement for an indel
for affinity maturation and bnAb activity in the VRC01-like
CH31 bnAb lineage.
Not all HIV-1-infected individuals make bnAbs, although it has
recently been shown that the ability tomake BnAbs is not dichot-
omous. That is, serum neutralization breadth is graded among
infected individuals (Hraber et al., 2014). What is not yet known
is whether there are host factors such as a genetic predisposition
that are responsible for the differences there are. Alternatively,
there may be as-yet-undetermined differences in the circum-
stances of the infection itself, such as total antigenic variability
or viral load that drives bnAb production. On the other hand,
there may be no host or pathogen factors that determine bnAb
status. Instead, bnAb status may be stochastic, driven essen-
tially by the stochastic nature of B cell affinity maturation itself.
In this study, we demonstrate that insertion and deletions occuricrobe 16, 304–313, September 10, 2014 ª2014 Elsevier Inc. 309
Table 2. Neutralization of HIV-1 Tier 1 and 2 Isolates by Members of CD4BS bnAb CH31 Clonal Lineage
Antibody B.MN.3 C.MW965 B.SF162 B.W61D C.C3347 C.DU172 A.Q23 A.TRO.11 MuLV
TCID50, ug/ml
HIV-1 Isolates Control
UCA >50 >50 >50 >50 >50 >50 >50 >50 >50
2FNGT3 >50 >50 >50 >50 >50 >50 >50 >50 >50
2JSKAU >50 >50 >50 >50 >50 >50 1.51 >50 >50
2GNM7S 30.1 >50 >50 >50 >50 >50 6.57 >50 >50
2H162G 0.03 6.78 1.07 2.62 10.4 5.61 0.08 0.94 >50
2H4SHE <0.023 2.45 0.402 0.023 3.86 1.63 0.085 0.75 >50
2G9LMX <0.023 1.43 0.443 0.326 6.48 7.7 0.07 0.95 >50
I1 3.86 10.2 1.34 >50 0.98 0.91 <0.23 0.46 >50
I2 7.19 15.8 1.68 >50 0.77 1.03 <0.23 0.54 >50
I3 5.55 9.09 1.12 >50 0.46 0.71 <0.23 0.47 >50
I4 2.26 5.38 0.77 >50 0.34 0.61 <0.23 0.33 >50
CH31 0.0225 0.993 0.121 8.34 0.17 1.15 <023 0.15 >50
2H162G – D1 >50 >50 >50 >50 >50 >50 3.19 >50 >50
2GNM7S+D.1 14.3 >50 49.7 38.3 >50 >50 4.21 >50 >50
2GNM7S+D2 16.2 >50 27.4 5.8 >50 >50 25.0 >50 >50
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Indels in HIV-1 Broadly Neutralizing Antibodiesat unusually high frequencies among bnAbs and that the occur-
rence of indels in HIV-1 bnAbs is determined by the degree
of SHM that occurs in HIV-1 infection, rather than by the
action of factors specific to those patients that have detectable
plasma bnAbs. By examining a total of 3,352,720 genomic
DNA sequencing reads from individuals with and without HIV-1
infection, we found that the rate of indels could be accounted
for by a single mutation frequency driving both point substitution
and indels in all groups, with only this single mutation frequency
varying among groups. Furthermore, the frequencies of both
indels and substitutions were only slightly higher in HIV-1-in-
fected patients, and there was no statistically significant differ-
ence between HIV-1-infected patients who have detectable
plasma bnAbs and those who did not. Moreover, we found
that the indel frequency depends on the substitution frequency
raised to a power greater than one. Mathematically, the relation-
ship between the frequency of insertions or deletions f and the
frequency of substitutions m is given by
f =gmb
where b > 1. The interpretation of this finding is that the excess
SHM frequency of bnAbs is sufficient by itself to account for
the increase in indel frequency. Thus, high indel frequency
does not represent a separate class of bnAb anomaly and
does not implicate unknown host factors or genetic predisposi-
tion to generate bnAbs. In this regard, we have recently per-
formed full exon sequencing on 50 bnAbs and 50 non-bnAbs
HIV-1-infected individuals and demonstrated no genome-wide
gene maturation associated with the ability to make bnAbs
(P. Shea, B.F.H., and D.B. Goldstein, unpublished data).
Previously, Krause et al. (2011) investigated the role of an
insertion in a human antibody against influenza HA by deleting
the insert while leaving all other somatic mutations intact and
comparing binding affinities between the two forms of the anti-
body. They found that the removal of the insertion increased310 Cell Host & Microbe 16, 304–313, September 10, 2014 ª2014 Elthe equilibrium dissociation constant 35-fold, largely through
increasing the kinetic dissociation rate. Pejchal et al. (2011)
deleted the inserts from two gp-120-binding anti-HIV-1 anti-
bodies, while leaving the rest of the molecules intact. They found
that the binding affinity for the antigen, and their ability to
neutralize the virus, were diminished by the removal of the insert.
Our goal and our findings were different from these studies in an
important way.While the previous groups of investigators sought
to determine the role of the insert in the function of the extant
antibodies, we sought to elucidate the role of the insertion event
in the affinity maturation of the bnAb clonal lineage. Thus, we
isolated lineage members from before and after the compound
insertion/deletion event and produced four constructs that re-
present possible intermediate forms. We found that after an
insertion or deletion event, point mutations continue to accumu-
late in the context of the indel. These postindel mutations may
have very different effects in the presence of the indel than
they would in its absence. Removing the insert from the mature
antibody did not return the antibody to its preindel state because
the postindel point mutations were still intact. Our studies more
closely approximate the history of the lineage at the time of the
indel’s occurrence.
Our analyses demonstrate that insertions and deletions are
prevalent at very high frequency in bnAbs, that indels can be crit-
ical for bnAb activity, and that indel frequency increases with,
and is predicted by, the frequency of SHM-mediated substitu-
tion. The last point is important because it suggests that the
continued accumulation of point mutations in HIV-infected indi-
viduals naturally leads to more substantial sequence alterations,
such as insertions and deletions, without additional genetic pre-
dispositions. It follows that a vaccine strategy specifically de-
signed to target and persistently activate bnAb precursors and
their descendants (Haynes et al., 2012) can induce the full spec-
trum of antibody somatic hypermutations seen in bnAbs and
may induce bnAbs as well.sevier Inc.
Figure 5. SPR-Estimated Kinetic Rate Constants
(A) Association rate, ka.
(B) Dissociation rate, kd for the tested antibodies as a function of evolutionary distance (expected nucleotide changes per base) from the inferred unmutated
common ancestor (UCA). Solid line segments indicate clonal descent. Dashed line segments indicate artificial descent by insertion or deletion of the respective
duplicon.
(C) The estimated dissociation, Kd (the ratio of the on rate to the off rate, Kd = kd/ka) versus the evolutionary distance from the UCA.
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Human Samples
DNA samples prepared from a total of 261 peripheral blood mononuclear
cell (PBMC) samples from 75 human subjects for analysis of VHDJH by
HTS. These individuals included 41 HIV-infected individuals (8 bnAb pro-
ducers and 33 non-bnAb producers) (Shen et al., 2009; Tomaras et al.,
2011; Morris et al., 2011; Moore et al., 2011), 16 healthy uninfected individ-
uals, and 18 healthy individuals vaccinated with the 2007–2008 or 2008–
2009 seasonal inactivated influenza vaccines as described (Moody et al.,
2011). Those characterized as bnAb producers had broad neutralizing
plasma antibodies by previously described criteria from the CHAVI chronic
HIV-1 infection cohort (Tomaras et al., 2011) and/or had bnAbs isolated
from blood B cells as described (Shen et al., 2009; Morris et al., 2011).
PBMC samples were used for DNA isolation for HTS from the influenza
vaccinated individuals taken before and 7 days and 21 days after vaccina-
tion (Moody et al., 2011) using the methods as described previously (Wram-
mert et al., 2008; Liao et al., 2009; Moody et al., 2011). All work related to
human subjects was in compliance with Institutional Review Board proto-
cols approved by the Duke University Health System Institutional Review
Board.
Inference of Unmutated Common Ancestor and Identification
of Clone Members
The inference of the VHDJH and VLJL of the unmutated common ancestor
(UCA) and intermediate antibodies of CD4BS bnAb VRC-CH30-34 clonal line-
age is described in detail elsewhere (Kepler, 2013; Kepler et al., 2014). Briefly,
we parameterize the VDJ rearrangement process in terms of its gene seg-
ments, recombination points, and n-regions. Given any multiple sequence
alignment A for the set of clonally related genes and any tree T describing a
purported history, we compute the likelihood for all parameter values, and
subsequently the posterior probabilities on the rearrangement parameters
conditional on A and T. We can then find the UA with the greatest posterior
probability and compute the maximum likelihood alignment A* and tree T*
given this UA, and then recompute the posterior probabilities on rearrange-
ment parameters conditional on A* and T*. We iterate the alternating condi-
tional optimizations until convergence is reached.
To infer likely clonal relatedness, we use the following statistical procedure.
Two sequences are regarded as potential relatives if they are inferred to have
used the same IGHV and IGHJ genes (without regard to allelic differences) and
if the number of differences between the two sequences in their CDR3 is not so
large that the following hypothesis is rejected. The hypothesis is that the two
CDR3 evolved from a common precursor and that along each of the two
branches, the mutation frequency is as estimated from the count of point mu-Cell Host & Mtations in IGHV alone. The test itself is a z test based on the Gaussian approx-
imation to the binomial.
Isolation of VHDJH and VL Genes and Expression of VHDJH and VLJL
Genes as Full-Length IgG1 Recombinant Monoclonal Antibodies
The VHDJH and VLJL gene segment pairs were isolated by RT/PCR from sorted
single plasma cells from PBMC collected from healthy blood donors and from
vaccinees 7 days after vaccination with either the 2007–2008 or 2008–2009
inactivated influenza vaccine according to a protocol approved by the Duke
University Health System Institutional Review Board (Moody et al., 2011).
The VHDJH and VLJL gene segment pairs of the observed VRC-CH30-34
were obtained as described previously (Wu et al., 2011). Additional VHDJH
were identified by HTS (Wu et al., 2011; Boyd et al., 2009). Clonally related
sequences derived from the observed CH31-34 and from the cDNA HTS
were combined and used to generate maximum-likelihood phylogenetic trees
(Figure 3C). The VHDJH gene sequences identified by HTS indicated in blue
boxes in Figure 1C have been synthesized and paired with intermediate-4 light
chain for production of recombinant monoclonal antibodies (mAbs) for testing
the binding and neutralizing activity using the method as described previously
(Liao et al., 2011, 2013).
Structural Analysis
A set of 11 antigen-bound structures for the following indel-containing bnAbs
were included in the analysis: VRC01, VRC03, VRC-CH31, VRC-PG04, NIH45-
46, 3BNC117, VRC-PG20, CH103, PG9, PGT128, and PGT135 (Wu et al.,
2010; Bonsignori et al., 2012; Falkowska et al., 2012; Scheid et al., 2011;
Chuang et al., 2013; Walker et al., 2009, 2011; Liao et al., 2013). A total of
18 indels were found in the 11 antibodies. For a given antibody, the distance
between an insertion and the corresponding antigen was computed as the
minimum heavy-atom (C, N, O, and S) distance between any residue part of
the insertion and any residue/glycan part of the antigen. Similarly, the distance
between an antibody deletion and the corresponding antigen was computed
as the minimum heavy-atom distance between either residue flanking the
deletion and any residue/glycan part of the antigen. For a given antibody,
loop residues were defined by the loop, bend, and turn categories in DSSP
(Kabsch and Sander, 1983), with distances computed as the minimum
heavy-atom distance between each loop residue and any residue/glycan in
the corresponding antigen. In the above analysis, missing residues in the input
structure were ignored.
Surface Plasmon Resonance Affinity and Kinetics Measurements
Binding Kd and rate constant (association rate ka, dissociation rate kd) mea-
surements of recombinant mAbs of VRC-CH30-34 clonal lineage to A244
D11 gp120 (Liao et al., 2013; Alam et al., 2013) were carried out on BIAcoreicrobe 16, 304–313, September 10, 2014 ª2014 Elsevier Inc. 311
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Indels in HIV-1 Broadly Neutralizing Antibodies3000 instruments as described previously (Alam et al., 2007, 2008, 2011). All
data analysis was performed using the BIAevaluation 4.1 analysis software
(GE Healthcare).
Neutralization Assays
Neutralizing antibody assays in TZM-bl cells were performed as described
previously (Montefiori, 2005). Neutralizing activity of plasma samples in eight
serial 3-fold dilutions starting at 1:20 dilution and for recombinant mAbs in
eight serial 3-fold dilutions starting at 50 ug/ml were tested against autologous
and heterologous HIV-1 Env-pseudotyped viruses in TZM-bl-based neutrali-
zation assays using the methods as described (Montefiori, 2005; Seaman
et al., 2010). The data were calculated as a reduction in luminescence units
compared with control wells and reported as IC50 in mg/ml for mAbs.
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